- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03884517 | Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer | terminated | Phase 1 | 5 | Bio-Thera SolutionsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00886782 | A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 28, 2023 | clinicaltrials |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor |
| terminated |
| Phase 1 / Phase 2 |
| 2 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Dec 27, 2022 |
| clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02801097 | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)(PAYLOAD) | terminated | Phase 1 | 28 | EpicentRx, Inc.INDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT03254732 | Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers | terminated | Phase 1 | 33 | Polaris GroupINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT03721679 | Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | terminated | Phase 1 / Phase 2 | 7 | Oncovir, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | terminated | Phase 1 | 29 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01632696 | Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors | terminated | Early Phase 1 | 11 | Peregrine PharmaceuticalsINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00977067 | A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | terminated | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 0 | Jun 21, 2017 | clinicaltrials |
| NCT02096341 | A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 | terminated | Phase 1 | 2 | EpicentRx, Inc.INDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00337376 | A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | terminated | Phase 1 | 23 | Yale UniversityOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT01416623 | A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 44 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 21, 2012 | clinicaltrials |
Data updated 22 days agoSource updated May 1, 2023source: clinicaltrials